Searchable abstracts of presentations at key conferences on calcified tissues

ba0001pp273 | Genetics | ECTS2013

Functional analysis of the two Runx3 promoters in osseous and non-osseous cells: implications for tissue/differentiation specific transcription of distinct isoforms

Conceicao Natercia , Simoes Brigite , Cancela M Leonor

The Runt-domain transcription factors Runx2 and Runx3 are known to drive chondrocyte maturation from prehypertrophic to the terminal stage. The RUNX family proteins form dimers with CBFb, and bind to consensus sequences of 5′-PuACCPuCa-3′ upstream of target genes to activate or repress transcription.To address the role of Runx3 transcription factor in zebrafish, we have isolated the different splice variants encoding distinct runx3 p...

ba0001pp296 | Muscle, physical activity and bone | ECTS2013

Body composition relationship in Korean old people

Choi Woong H , Hong Sang M

Background: Recently, the prevalence of osteoporosis and sarcopenia in the elderly has dramatically increased. However the relationship between theses disease is not clear.Object: We aimed to determine the independent relations of muscle mass to osteoporosis (femur neck) in relation to body weight, fat mass, and other confounders.Design: We analyzed body composition and BMD data of 570 males and 734 females who are older than 65 ye...

ba0002p159 | (1) | ICCBH2013

Novel SLC34A3 mutation causing mild hypophosphataemia, hypercalciuria and nephrolithiasis but no clinical or radiological evidence of rickets

Steele Caroline , Bradbury Mark , Mughal M Zulf

Background: Genetic disorders of mineral metabolism causing nephrolithiasis and bone abnormalities are uncommon and have a varied clinical spectrum. Hypophosphataemic rickets with hypercalciuria (HHRH) is a rare autosomal-recessive condition, typically presenting with severe rickets and hypophosphataemia. Milder forms can present with hypercalciuria and nephrolithiasis without bone disease. The underlying pathophysiology is due to mutations in the SLC34A3 gene, which encodes t...

ba0004p125 | (1) | ICCBH2015

Vitamin D status of gastrostomy-fed children with special needs

Kuter Hayley , Das Geeta , Mughal M Zulf

Background: Children with special needs may be greater risk of vitamin D deficiency due to decreased mobility and outdoor play, concomitant medications that increase catabolism of vitamin D, reduced nutritional intake and low body weight. Gastrostomy-fed children receiving a nutritionally complete formula may still be at risk of vitamin D deficiency due to the above factors.Objective: The objective of this study is to assess the vitamin D status of speci...

ba0004p133 | (1) | ICCBH2015

Fibrodysplasia ossificans progressiva: disabling but now treatable

Keen Richard , Jacobs Benjamin , Mughal M Zulf

Background: Fibrodysplasia ossificans progressiva (FOP) is a rare condition characterised by congenital malformation of the great toes and progressive heterotopic endochondral ossification. The disease progresses with episodic flare-ups, resulting in disabling cumulative immobility. The discovery of the ACVR1 gene as the cause of FOP has allowed identification of therapeutic targets. Palovarotene, a retinoic acid receptor gamma agonist, is in phase 2 clinical trials.<...

ba0005p137 | Cell biology: osteoblasts and bone formation | ECTS2016

Delta-like 1/fetal antigen 1 (DLK1/FA1) inhibits BMP2-induced osteoblast differentiation by modulating Nfκb signaling pathway: a novel mechanism for regulation of bone formation

Qiu Weimin , Abdallah Basem M. , Kassem Moustapha

Delta-like 1/fetal antigen-1 (DLK1/FA1) is a negative regulator of bone mass in vivo as it inhibits osteoblast (OB) and stimulates osteoclast differentiation. However, the molecular mechanisms underlying these effects are not known. Thus, we studied the effect of DLK1/FA1 on different signaling pathways known to regulate OB differentiation. We identified DLK1/FA1 as an inhibitor of BMP2-induced OB differentiation. Stable overexpression of DLK1/FA1 in C2C12 cells or th...

ba0007p136 | (1) | ICCBH2019

Intravenous bisphosphonate treatment in severe infantile hypercalcemia associated with Williams Syndrome

Guarneri Alissa M , Patel Nisha , Bowden Sasigarn A

Background: Infantile hypercalcemia occurs in ~15% of patients with Williams Syndrome (WS) and is typically mild. Severe hypercalcemia has been reported in infants/toddlers with WS, requiring treatment with intravenous (IV) saline hydration, furosemide, calcitonin, calcium and vitamin D restriction, and in some cases IV bisphosphonates.Presenting problem: Three cases of infants with WS age 9–13 months presented with severe hypercalcemia, failure to ...

ba0001pp67 | Bone development/growth and fracture repair | ECTS2013

Hip fracture induces a transient appearance of circulating mesenchymal stem cells

Heino Terhi J , Sederquist Bettina , Aro Hannu T

We have previously demonstrated the presence of circulating mesenchymal stem cells (MSCs) in fracture patients. However, the exact time for their appearance in circulation remains unknown. Nine patients (five females, four males, age 70±12 years, range 55–89 years) with a fresh femoral neck fracture were recruited in the study, which was approved by the local ethical committee. Bone marrow (BM) sample drawn from the iliac crest of all patients served as the individua...

ba0001pp160 | Cancer and bone: basic, translational and clinical | ECTS2013

Glucose ceramide synthase inhibitors prevent osteoclast activation and limit myeloma-induced osteolytic lesions

Ersek Adel , Xu Ke , Karadimitris Anastasios , Horwood Nicole J

Glycosphingolipids (GSL) are essential structural components of mammalian cell membranes and lipid rafts that exert pleiotropic effects on cell survival, proliferation, and differentiation. Cancer associated GSL have been shown to promote tumor growth, angiogenesis, and metastasis; however their role in osteoclast (OC) activation and the development of osteolytic bone diseases such as multiple myeloma are not known. We investigated the hypothesis that GSL contribute to OC acti...